COMPANY PROFILE

THERAVECTYS

THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.

Paris, FranceFounded 2005Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About THERAVECTYS

Theravectys operates in the biotech sector, focusing on the development of T cell vaccines using a proprietary lentiviral vector platform. The company targets both prophylactic and therapeutic vaccines, addressing critical unmet medical needs such as chronic infections and cancers, including the global HIV epidemic. By leveraging over 20 years of research, Theravectys aims to transform the field of vaccinology through strategic industrial partnerships and collaborations, including a joint laboratory with the Pasteur Institute. The business model centers on preclinical proof of concept across a broad range of indications, moving products through clinical stages and regulatory approval. Revenue is generated through global licensing and partnerships, positioning Theravectys as a potential game-changer in global health.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2005
Headquarters: Paris, France
Employees: 16
Open positions: None listed
Dealroom signal: 69.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Tea, Wholesale, Intellectual Property, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Feb 2021	$18M	$73M	Undisclosed	↗
EARLY VC✓Equity / VC	Jan 2015	$2.1M	$8.4M	Bpifrance	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

THERAVECTYS website traffic

Latest recorded traffic for THERAVECTYS is 2.3K monthly website visits, up 167.4% over the last three months. THERAVECTYS's team declined 15.8% over the past year.

Latest monthly visits2.3K 3-month web change+167.4% 1-year team growth-15.8%

Monthly website visitsJan 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational	22	$29M	$88M
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
TOTollysDevelopment of innovative immunotherapies targeting cancer through the modulation of the TLR3 receptor	Lyon, France	Closed
STStimunityTurn cancer immunotherapies active in most patient	Paris, France	Operational
PEPep-TherapyDeveloping first-in-class peptides as targeted therapies in oncology	Paris, France	Operational
ITImCheck TherapeuticsDesigning and developing a new generation of immunotherapy antibodies	Marseille, France	Acquired
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational